Share Price and Basic Stock Data
Last Updated: December 13, 2025, 8:52 am
| PEG Ratio | -1.52 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sanofi India Ltd operates in the pharmaceuticals sector, a critical area that has seen fluctuating demand dynamics, especially post-pandemic. The company’s recent sales figures tell a story of volatility; for instance, sales stood at ₹699 Cr in June 2022 but dropped to ₹469 Cr by December 2023, reflecting a general downturn in revenue generation. The trailing twelve months (TTM) sales are recorded at ₹1,981 Cr, a significant decrease from the ₹2,770 Cr reported for the fiscal year ending December 2022. This decline can be attributed to several factors, including changing healthcare policies, competition, and potential supply chain issues. Nevertheless, there were signs of recovery in the latter half of 2024, with sales rising to ₹536 Cr in March 2025, indicating the company’s resilience in a challenging market.
Profitability and Efficiency Metrics
Examining the profitability, Sanofi India has reported a net profit of ₹362 Cr for the TTM, reflecting a decline from the ₹621 Cr recorded in the fiscal year ending December 2022. Despite this, the company maintains a robust return on equity (ROE) of 47.2% and a return on capital employed (ROCE) of 49.2%, suggesting that it still generates significant returns relative to its equity and capital base. The operating profit margin (OPM) has also shown some fluctuation, hitting a high of 31% in March 2023, before settling at 23% in the latest reports. The efficiency metrics, particularly an interest coverage ratio of 338.20x, indicate that the company is comfortably managing its operational costs and has ample capacity to cover interest expenses, a positive sign for investors.
Balance Sheet Strength and Financial Ratios
Sanofi India’s balance sheet appears strong, with total borrowings remaining low at ₹21 Cr, which is negligible compared to its reserves of ₹759 Cr. This low leverage not only enhances financial stability but also provides the company with the flexibility to invest in growth opportunities without the burden of heavy debt. The price-to-book value ratio of 16.36x indicates that the stock may be trading at a premium relative to its book value, reflecting investor confidence but also suggesting a potential overvaluation. The company’s cash conversion cycle (CCC) has increased significantly to 77 days, which may raise concerns about working capital management, especially given the reported increase in inventory days. This aspect could reflect inefficiencies that might need addressing to optimize cash flow.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sanofi India reveals a stable structure with promoters holding 60.40% of the equity. This level of promoter commitment often instills confidence among retail investors. Meanwhile, domestic institutional investors (DIIs) hold 22.28%, suggesting that institutional interest remains strong, although foreign institutional investors (FIIs) have slightly reduced their stake to 5.57%. The number of shareholders has also seen fluctuations, from 74,593 in December 2022 to 71,395 recently, indicating some consolidation. This dynamic might reflect broader market sentiments or sector-specific trends, but the overall stability in promoter holding is a reassuring factor for investors looking for long-term commitment from the management.
Outlook, Risks, and Final Insight
Looking ahead, Sanofi India faces both opportunities and challenges. On one hand, the pharmaceutical sector is poised for growth due to increasing healthcare needs and advancements in medical technology. On the other hand, potential risks include regulatory changes, pricing pressures, and the competitive landscape that could impact margins and market share. Investors might consider the company’s strong fundamentals, such as high ROE and low debt, as positive indicators, but should also remain cautious about the volatility in sales and the rising cash conversion cycle. Overall, while Sanofi India has demonstrated resilience in a challenging environment, the evolving market dynamics necessitate a careful approach for investors weighing their options in the pharmaceutical space.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 237/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,250 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,476.95 Cr | 1,156.03 | 52.77 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 699 | 692 | 672 | 736 | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 |
| Expenses | 538 | 510 | 505 | 507 | 393 | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 |
| Operating Profit | 161 | 182 | 167 | 230 | 122 | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 |
| OPM % | 23% | 26% | 25% | 31% | 24% | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% |
| Other Income | 16 | 11 | 34 | 44 | 57 | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 |
| Profit before tax | 166 | 182 | 190 | 264 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 |
| Tax % | 27% | 28% | 31% | 28% | 27% | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% |
| Net Profit | 120 | 131 | 131 | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 |
| EPS in Rs | 52.35 | 56.91 | 56.91 | 82.78 | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.70 | 51.96 | 30.22 |
Last Updated: August 1, 2025, 12:30 pm
Below is a detailed analysis of the quarterly data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 406.00 Cr.. The value appears to be declining and may need further review. It has decreased from 536.00 Cr. (Mar 2025) to 406.00 Cr., marking a decrease of 130.00 Cr..
- For Expenses, as of Jun 2025, the value is 311.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 364.00 Cr. (Mar 2025) to 311.00 Cr., marking a decrease of 53.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 77.00 Cr..
- For OPM %, as of Jun 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 32.00% (Mar 2025) to 23.00%, marking a decrease of 9.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 6.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 94.00 Cr.. The value appears to be declining and may need further review. It has decreased from 165.00 Cr. (Mar 2025) to 94.00 Cr., marking a decrease of 71.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Mar 2025) to 26.00%, marking a decrease of 2.00%.
- For Net Profit, as of Jun 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 50.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 30.22. The value appears to be declining and may need further review. It has decreased from 51.96 (Mar 2025) to 30.22, marking a decrease of 21.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:08 pm
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,809 | 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 1,996 | 2,013 | 1,981 |
| Expenses | 1,411 | 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 1,508 | 1,522 | 1,476 |
| Operating Profit | 398 | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 488 | 491 | 505 |
| OPM % | 22% | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 24% | 24% | 25% |
| Other Income | 83 | 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 318 | 79 | 28 |
| Interest | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 92 | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 36 | 37 | 37 |
| Profit before tax | 388 | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 767 | 531 | 494 |
| Tax % | 32% | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 21% | 22% | |
| Net Profit | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 414 | 362 |
| EPS in Rs | 115.30 | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.26 | 179.78 | 157.62 |
| Dividend Payout % | 39% | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% | 65% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -8% |
| 3 Years: | -12% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | -9% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | 11% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 32% |
| 3 Years: | 41% |
| Last Year: | 47% |
Last Updated: September 5, 2025, 1:25 pm
Balance Sheet
Last Updated: August 11, 2025, 2:43 pm
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 1,324 | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 | 759 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 | 21 |
| Other Liabilities | 532 | 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 | 436 |
| Total Liabilities | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
| Fixed Assets | 699 | 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 | 309 |
| CWIP | 136 | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Other Assets | 1,043 | 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,382 | 1,281 | 914 |
| Total Assets | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
Below is a detailed analysis of the balance sheet data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Equity Capital, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 23.00 Cr..
- For Reserves, as of Jun 2025, the value is 759.00 Cr.. The value appears to be declining and may need further review. It has decreased from 838.00 Cr. (Dec 2024) to 759.00 Cr., marking a decrease of 79.00 Cr..
- For Borrowings, as of Jun 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 19.00 Cr. (Dec 2024) to 21.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Jun 2025, the value is 436.00 Cr.. The value appears to be improving (decreasing). It has decreased from 732.00 Cr. (Dec 2024) to 436.00 Cr., marking a decrease of 296.00 Cr..
- For Total Liabilities, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
- For Fixed Assets, as of Jun 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 312.00 Cr. (Dec 2024) to 309.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Other Assets, as of Jun 2025, the value is 914.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,281.00 Cr. (Dec 2024) to 914.00 Cr., marking a decrease of 367.00 Cr..
- For Total Assets, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
Notably, the Reserves (759.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 398.00 | 339.00 | 376.00 | 535.00 | 538.00 | 625.00 | 667.00 | 693.00 | 737.00 | 680.00 | 469.00 | 472.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 24 | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 24 | 42 |
| Inventory Days | 151 | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 254 | 186 |
| Days Payable | 83 | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 112 | 151 |
| Cash Conversion Cycle | 92 | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 167 | 77 |
| Working Capital Days | 43 | 26 | 9 | 79 | 17 | 18 | 35 | -8 | -20 | -19 | 35 | 20 |
| ROCE % | 29% | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 44% | 49% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 251,576 | 0.24 | 120.27 | 161,000 | 2025-12-07 15:45:16 | 56.26% |
| Aditya Birla Sun Life Large Cap Fund | 250,365 | 0.39 | 119.69 | N/A | N/A | N/A |
| SBI Midcap Fund | 250,165 | 0.52 | 119.59 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 230,272 | 1.32 | 110.08 | 236,008 | 2025-12-08 04:19:42 | -2.43% |
| Nippon India Growth Mid Cap Fund | 226,766 | 0.26 | 108.41 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 213,992 | 0.15 | 102.3 | 196,342 | 2025-12-08 07:42:13 | 8.99% |
| Nippon India Multi Cap Fund | 152,371 | 0.15 | 72.84 | 152,371 | 2025-04-22 17:25:21 | 0% |
| SBI ELSS Tax Saver Fund | 147,988 | 0.22 | 70.75 | N/A | N/A | N/A |
| Aditya Birla Sun Life Balanced Advantage Fund | 81,404 | 0.45 | 38.92 | N/A | N/A | N/A |
| Aditya Birla Sun Life Consumption Fund | 75,252 | 0.55 | 35.98 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Dec 24 | Dec 23 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 179.46 | 261.78 |
| Diluted EPS (Rs.) | 179.46 | 261.78 |
| Cash EPS (Rs.) | 195.65 | 279.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Revenue From Operations / Share (Rs.) | 875.30 | 1239.61 |
| PBDIT / Share (Rs.) | 220.57 | 377.83 |
| PBIT / Share (Rs.) | 204.61 | 360.61 |
| PBT / Share (Rs.) | 187.57 | 367.61 |
| Net Profit / Share (Rs.) | 179.69 | 262.13 |
| NP After MI And SOA / Share (Rs.) | 179.69 | 262.13 |
| PBDIT Margin (%) | 25.19 | 30.47 |
| PBIT Margin (%) | 23.37 | 29.09 |
| PBT Margin (%) | 21.42 | 29.65 |
| Net Profit Margin (%) | 20.52 | 21.14 |
| NP After MI And SOA Margin (%) | 20.52 | 21.14 |
| Return on Networth / Equity (%) | 48.02 | 59.38 |
| Return on Capital Employeed (%) | 52.72 | 77.98 |
| Return On Assets (%) | 25.64 | 35.15 |
| Asset Turnover Ratio (%) | 1.21 | 0.00 |
| Current Ratio (X) | 1.57 | 1.92 |
| Quick Ratio (X) | 0.87 | 0.89 |
| Inventory Turnover Ratio (X) | 0.60 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 139.85 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 131.23 |
| Earning Retention Ratio (%) | 0.00 | -39.85 |
| Cash Earning Retention Ratio (%) | 0.00 | -31.23 |
| Interest Coverage Ratio (X) | 338.20 | 511.18 |
| Interest Coverage Ratio (Post Tax) (X) | 235.27 | 345.18 |
| Enterprise Value (Cr.) | 13783.39 | 18147.83 |
| EV / Net Operating Revenue (X) | 6.85 | 6.37 |
| EV / EBITDA (X) | 27.17 | 20.88 |
| MarketCap / Net Operating Revenue (X) | 6.99 | 6.51 |
| Retention Ratios (%) | 0.00 | -39.85 |
| Price / BV (X) | 16.36 | 18.28 |
| Price / Net Operating Revenue (X) | 6.99 | 6.51 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Sanofi India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Diluted EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Cash EPS (Rs.), as of Dec 24, the value is 195.65. This value is within the healthy range. It has decreased from 279.35 (Dec 23) to 195.65, marking a decrease of 83.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 875.30. It has decreased from 1,239.61 (Dec 23) to 875.30, marking a decrease of 364.31.
- For PBDIT / Share (Rs.), as of Dec 24, the value is 220.57. This value is within the healthy range. It has decreased from 377.83 (Dec 23) to 220.57, marking a decrease of 157.26.
- For PBIT / Share (Rs.), as of Dec 24, the value is 204.61. This value is within the healthy range. It has decreased from 360.61 (Dec 23) to 204.61, marking a decrease of 156.00.
- For PBT / Share (Rs.), as of Dec 24, the value is 187.57. This value is within the healthy range. It has decreased from 367.61 (Dec 23) to 187.57, marking a decrease of 180.04.
- For Net Profit / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For NP After MI And SOA / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For PBDIT Margin (%), as of Dec 24, the value is 25.19. This value is within the healthy range. It has decreased from 30.47 (Dec 23) to 25.19, marking a decrease of 5.28.
- For PBIT Margin (%), as of Dec 24, the value is 23.37. This value exceeds the healthy maximum of 20. It has decreased from 29.09 (Dec 23) to 23.37, marking a decrease of 5.72.
- For PBT Margin (%), as of Dec 24, the value is 21.42. This value is within the healthy range. It has decreased from 29.65 (Dec 23) to 21.42, marking a decrease of 8.23.
- For Net Profit Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 10. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 20. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Dec 24, the value is 48.02. This value is within the healthy range. It has decreased from 59.38 (Dec 23) to 48.02, marking a decrease of 11.36.
- For Return on Capital Employeed (%), as of Dec 24, the value is 52.72. This value is within the healthy range. It has decreased from 77.98 (Dec 23) to 52.72, marking a decrease of 25.26.
- For Return On Assets (%), as of Dec 24, the value is 25.64. This value is within the healthy range. It has decreased from 35.15 (Dec 23) to 25.64, marking a decrease of 9.51.
- For Asset Turnover Ratio (%), as of Dec 24, the value is 1.21. It has increased from 0.00 (Dec 23) to 1.21, marking an increase of 1.21.
- For Current Ratio (X), as of Dec 24, the value is 1.57. This value is within the healthy range. It has decreased from 1.92 (Dec 23) to 1.57, marking a decrease of 0.35.
- For Quick Ratio (X), as of Dec 24, the value is 0.87. This value is below the healthy minimum of 1. It has decreased from 0.89 (Dec 23) to 0.87, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Dec 24, the value is 0.60. This value is below the healthy minimum of 4. It has increased from 0.00 (Dec 23) to 0.60, marking an increase of 0.60.
- For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 139.85 (Dec 23) to 0.00, marking a decrease of 139.85.
- For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 131.23 (Dec 23) to 0.00, marking a decrease of 131.23.
- For Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Cash Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -31.23 (Dec 23) to 0.00, marking an increase of 31.23.
- For Interest Coverage Ratio (X), as of Dec 24, the value is 338.20. This value is within the healthy range. It has decreased from 511.18 (Dec 23) to 338.20, marking a decrease of 172.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 235.27. This value is within the healthy range. It has decreased from 345.18 (Dec 23) to 235.27, marking a decrease of 109.91.
- For Enterprise Value (Cr.), as of Dec 24, the value is 13,783.39. It has decreased from 18,147.83 (Dec 23) to 13,783.39, marking a decrease of 4,364.44.
- For EV / Net Operating Revenue (X), as of Dec 24, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 6.37 (Dec 23) to 6.85, marking an increase of 0.48.
- For EV / EBITDA (X), as of Dec 24, the value is 27.17. This value exceeds the healthy maximum of 15. It has increased from 20.88 (Dec 23) to 27.17, marking an increase of 6.29.
- For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For Retention Ratios (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 30. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Price / BV (X), as of Dec 24, the value is 16.36. This value exceeds the healthy maximum of 3. It has decreased from 18.28 (Dec 23) to 16.36, marking a decrease of 1.92.
- For Price / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Dec 23) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
- Net Profit Margin: 20.52%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 52.72% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 48.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 235.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.87
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.5 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.52%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sanofi House, Mumbai Maharashtra 400072 | igrc.sil@sanofi.com http://www.sanofiindialtd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Narayan | Chairman & Ind.Director |
| Mr. Rodolfo Hrosz | Managing Director |
| Mr. Rachid Ayari | WholeTime Director & CFO |
| Ms. Renee Amonkar | Whole Time Director |
| Mr. Vaibhav Karandikar | Non Executive Director |
| Mrs. Usha Thorat | Independent Director |
| Mr. Rahul Bhatnagar | Independent Director |
FAQ
What is the intrinsic value of Sanofi India Ltd?
Sanofi India Ltd's intrinsic value (as of 13 December 2025) is 3496.08 which is 17.58% lower the current market price of 4,242.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 9,770 Cr. market cap, FY2025-2026 high/low of 6,718/4,146, reserves of ₹759 Cr, and liabilities of 1,239 Cr.
What is the Market Cap of Sanofi India Ltd?
The Market Cap of Sanofi India Ltd is 9,770 Cr..
What is the current Stock Price of Sanofi India Ltd as on 13 December 2025?
The current stock price of Sanofi India Ltd as on 13 December 2025 is 4,242.
What is the High / Low of Sanofi India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sanofi India Ltd stocks is 6,718/4,146.
What is the Stock P/E of Sanofi India Ltd?
The Stock P/E of Sanofi India Ltd is 26.5.
What is the Book Value of Sanofi India Ltd?
The Book Value of Sanofi India Ltd is 340.
What is the Dividend Yield of Sanofi India Ltd?
The Dividend Yield of Sanofi India Ltd is 2.76 %.
What is the ROCE of Sanofi India Ltd?
The ROCE of Sanofi India Ltd is 49.2 %.
What is the ROE of Sanofi India Ltd?
The ROE of Sanofi India Ltd is 47.2 %.
What is the Face Value of Sanofi India Ltd?
The Face Value of Sanofi India Ltd is 10.0.